Noven is a fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise

About Noven - Timeline

Noven – 1987 to Today

Noven's history began in 1987 in Miami, Florida with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to benefit patients across a range of therapeutic conditions. Today, Noven is the U.S. platform for Hisamitsu, the world's largest patch manufacturer, with fully-integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and central nervous system (CNS) disorders.

July 2016
Brisdelle® and Pexeva® acquired by Sebela Pharmaceuticals
February 2015
New Minivelle® (Estradiol Transdermal System) 0.025 mg/day Dose Now Available by Prescription in U.S. Pharmacies
November 2013
Launch of Brisdelle®
June 2013
Brisdelle® approved by the FDA
January 2013
Noven Women's Health team launches Minivelle®
December 2012
Noven acquires Minivelle®, establishes Women's Health sales team
October 2012
Minivelle®, world's smallest estrogen patch, approved by FDA
2011
Noven's Northeast operations consolidated in Empire State Building co-headquarters
2010
Noven reacquires Daytrana® from Shire
2010
Hisamitsu Carlsbad facility integrated with Noven operations
2009
Noven acquired by Hisamitsu Pharmaceuticals; public company status concludes
2007
Noven acquires JDS Pharmaceuticals, expanding its portfolio and sales capabilities
2006
Shire and Noven launch Daytrana®
2003
Shire licenses Noven's Daytrana® patch for ADHD
1999
Launch of Vivelle-Dot®, the world's smallest estrogen patch at the time
1998
Launch of CombiPatch®, the first combination (two-drug) patch
1998
Formation of Novogyne joint venture in Women's Health
1996
Launch of Vivelle®, the first adhesive matrix estrogen patch
1988
Noven becomes a public company
1987
Noven founded by Steven Sablotsky
Minivelle Package Japan USA Flags Daytrana PackageVivelle Dot Vivelle Conveyor Vivelle Dot Approval Noven's Building Noven Company

Fast Facts

Core Business:

Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

Year of Incorporation:

1987

Employees:

Over 325

Chief Executive Officer:

Jeff Mihm

Media, General Business
& Other Inquiries:

Tel: 305-253-1916
CorporateAffairs@noven.com

Partnering and Other Business Development Opportunities

Tel: 551-233-2700
BusDev@noven.com

Physican Payment
Sunshine Act Inquiries:

Aggspend@noven.com

Employment Inquiries:

Rory Kelly
Associate Director – Recruiting
rkelly@noven.com
Careers Page

Community Support:

Corporate Social Responsibility

Affiliated Companies:

Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.

Noven's commercialized products are marketed and sold through Noven Therapeutics, LLC.

Grove Pharmaceuticals is the generic division of Noven Therapeutics, LLC.